ImpediMed Wins Frost & Sullivan’s 2025 Technology Innovation Leadership Award: A Game-Changer in Healthcare Solutions

ImpediMed, a top player in medical technology, has just received the Frost & Sullivan 2025 North American Technology Innovation Leadership Award. This award highlights their efforts in improving patient care through their SOZO^® Digital Health Platform, which uses non-invasive bioimpedance spectroscopy to monitor body composition and fluid levels. This technology is especially beneficial for managing lymphedema after breast cancer.

ImpediMed stands out as the only company with FDA-cleared bioimpedance spectroscopy technology for assessing breast cancer-related lymphedema (BCRL). Their approach is backed by extensive clinical research and guidelines.

“Our bioimpedance spectroscopy accurately identifies different fluid types and early changes, crucial for managing breast cancer-related lymphedema,” said Isai Pratha Karthik, Ph.D., from Frost & Sullivan. This technology measures impedance at 256 frequencies, giving healthcare providers a clear picture of fluid and tissue characteristics to guide their decisions.

Lymphedema is a painful swelling that often follows cancer treatments. Around 58% of breast cancer patients are at risk for developing it. The risk increases with certain treatments. Bioimpedance spectroscopy offers a fast, non-invasive method to identify fluid changes in the body long before any visible signs emerge.

A significant study, known as the PREVENT trial, tracked over 1,200 patients and demonstrated that early detection using BIS technology kept chronic lymphedema at bay in 92% of cases. This proves that SOZO could be a vital tool in oncology clinics around the world.

“Our SOZO platform is changing how clinicians view and manage body composition and fluid levels, leading to better patient care,” said Dr. Parmjot Bains, MD, Managing Director and CEO of ImpediMed. This award highlights their dedication to improving patient lives and showcases their leadership in the field.

ImpediMed’s technology is widely recognized for its effectiveness, with health insurers in the U.S. now covering it for over 257 million lives.

This year, the National Accreditation Program for Breast Centers (NABPC) updated its standards to include lymphedema prevention programs that apply bioimpedance spectroscopy as an option for early detection.

About SOZO Digital Health Platform

SOZO is the most advanced non-invasive bioimpedance spectroscopy device. It gives a clear view of fluid levels and tissue makeup in under 30 seconds. By measuring 256 data points across various frequencies, SOZO provides immediate results that can be accessed and shared throughout healthcare systems. It’s designed to assist in the early detection of secondary lymphedema and offers insights for patients with heart or kidney issues, all through one device.

About ImpediMed

ImpediMed is a global leader in medical technology, creating devices that use bioimpedance spectroscopy for quick and effective assessment of fluid status and tissue composition. They focus on addressing the specific needs of those affected by secondary lymphedema, particularly post-breast cancer. With its SOZO® platform and L-Dex®, ImpediMed is setting the benchmark for early detection and management of BCRL.

About Frost & Sullivan

Frost & Sullivan has been a trusted name for over sixty years, helping organizations understand changes in the economy and identify disruptive technologies, megatrends, and new business models to create growth opportunities.